John Libbey Eurotext

Epidiolex-induced skin rash Volume 22, issue 4, August 2020

Figures

  • Figure 1
  • Figure 2
Authors
The Ohio State University Wexner Medical Center, Neurology department, Columbus, Ohio, USA
* Correspondence: Jaysingh Singh The Ohio State University Wexner Medical Center, Neurology department, Columbus, Ohio, USA

Epidiolex® (cannabidiol, aka CBD) is a recently approved FDA prescription drug for the treatment of epilepsy associated with Lennox-Gastaut and Dravet syndromes, and is increasingly used for treatment-resistant epilepsy. Rash was rarely reported in Epidiolex® clinical trial data. We report a case of Epidiolex®-related skin rash that developed in a delayed fashion in a 23-year-old female with medically refractory epilepsy. We also review the potential mechanism of Epidiolex®-related skin rash.